368 related articles for article (PubMed ID: 16278840)
1. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
2. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
3. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
4. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.
Cerbai F; Giovannini MG; Melani C; Enz A; Pepeu G
Eur J Pharmacol; 2007 Oct; 572(2-3):142-50. PubMed ID: 17643410
[TBL] [Abstract][Full Text] [Related]
5. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex.
Kuhl DE; Minoshima S; Frey KA; Foster NL; Kilbourn MR; Koeppe RA
Ann Neurol; 2000 Sep; 48(3):391-5. PubMed ID: 10976649
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity.
Snyder SE; Gunupudi N; Sherman PS; Butch ER; Skaddan MB; Kilbourn MR; Koeppe RA; Kuhl DE
J Cereb Blood Flow Metab; 2001 Feb; 21(2):132-43. PubMed ID: 11176278
[TBL] [Abstract][Full Text] [Related]
7. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Wright CI; Geula C; Mesulam MM
Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
10. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease.
Bohnen NI; Kaufer DI; Hendrickson R; Ivanco LS; Lopresti B; Davis JG; Constantine G; Mathis CA; Moore RY; DeKosky ST
Neurosci Lett; 2005 May 20-27; 380(1-2):127-32. PubMed ID: 15854764
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
12. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
14. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives.
Rampa A; Bisi A; Valenti P; Recanatini M; Cavalli A; Andrisano V; Cavrini V; Fin L; Buriani A; Giusti P
J Med Chem; 1998 Oct; 41(21):3976-86. PubMed ID: 9767635
[TBL] [Abstract][Full Text] [Related]
15. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Darreh-Shori T; Forsberg A; Modiri N; Andreasen N; Blennow K; Kamil C; Ahmed H; Almkvist O; Långström B; Nordberg A
Neurobiol Aging; 2011 Dec; 32(12):2320.e15-32. PubMed ID: 20538374
[TBL] [Abstract][Full Text] [Related]
16. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
17. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
Darreh-Shori T; Brimijoin S; Kadir A; Almkvist O; Nordberg A
Neurobiol Dis; 2006 Nov; 24(2):326-33. PubMed ID: 16973370
[TBL] [Abstract][Full Text] [Related]
18. Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease.
Eggers C; Herholz K; Kalbe E; Heiss WD
Neurosci Lett; 2006 Nov; 408(1):46-50. PubMed ID: 16996687
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and blood metabolism of 1-11C-methyl-4-piperidinyl n-butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET.
Roivainen A; Rinne J; Virta J; Järvenpää T; Salomäki S; Yu M; Någren K
J Nucl Med; 2004 Dec; 45(12):2032-9. PubMed ID: 15585478
[TBL] [Abstract][Full Text] [Related]
20. Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: effects of sex hormone withdrawal.
Alves-Amaral G; Pires-Oliveira M; Andrade-Lopes AL; Chiavegatti T; Godinho RO
Chem Biol Interact; 2010 Jun; 186(1):9-15. PubMed ID: 20399201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
